ClinicalTrials.gg
CompletedNCT03910660Updated Nov 10, 2026Results posted

A Trial of Talabostat (BXCL701) and Pembrolizumab in Participants With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype

A Phase 1/2 interventional study of Talabostat and Pembrolizumab in Prostate Cancer, Neuroendocrine Tumors and Small Cell Carcinoma, sponsored by BioXcel Therapeutics Inc. Completed at 12 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by BioXcel Therapeutics Inc · Phase 1/2, Interventional, and Treatment

How we know · 11 judgments · one reading being read again

Updated Nov 10, 2026Results postedStudy documents posted+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
97
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,597 studies in Prostatic Neoplasms with a site in United States — 605 open to participants now, 974 under way, 100 of them phase 3. Prostatic Neoplasms · United States.

Enrollment
970th of 3,024
97 · median 48
Started
2019
with 159 others
Phase 1/2
284 of 3,597
63 open now
Registered
2,331st of 3,597
by date

Among the 3,597 studies in Prostatic Neoplasms with a site in United States, this one is the 970th largest by enrollment of the 3,024 interventional ones that give a count, is one of 160 that started in 2019, is one of 284 in phase 1/2, and was the 2,331st registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

605 of the 3,597 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

600 more — sign in →

All 605 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,597 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

An open-label, multicenter, Phase 1b/2 study to identify the recommended Phase 2 dose and assess the efficacy and safety of talabostat administered orally, as monotherapy and in combination with pembrolizumab, in participants with mCRPC. Participants enrolled in the Phase 2a portion of the study will have either SCNC (Cohort A) or adenocarcinoma phenotype (Cohort B), while the Phase 2b randomized portion of the study will enroll only the histologic subtype(s) showing preliminary evidence in Phase 2a. The study will also assess other efficacy parameters, such as radiographic progression-free survival (rPFS), prostate-specific antigen progression-free survival (PSA PFS), overall survival (OS), and duration of response (DOR), as well as the safety of the combined treatment.

Read the detailed description

The study will consist of three components.

  1. Phase 1b: Safety and tolerability of the combination of talabostat administered once daily (QD) on Days 1 to 14 of a 21-day cycle plus pembrolizumab 200 milligrams (mg) administered intravenously (IV) on Day 1 of every 21 days will be assessed and confirmed in participants with mCRPC. In the first cohort enrolled in the study, the initial dose level of talabostat will be 0.4 mg; if there are no safety concerns, this will be escalated to a total daily dose of 0.6 mg.
  2. Phase 2a (Simon 2 Stage): Participants will be treated with talabostat in combination with pembrolizumab. Participants will be grouped in 1 of 2 cohorts based on phenotype.

    • Cohort A: Participants with any Small Cell/Neuroendocrine features, either de novo or treatment-emergent included mixed SCNC.
    • Cohort B: Cohort B: Participants with adenocarcinoma and no evidence of small cell or neuroendocrine features.

Phase 2b (for the histologic subtype[s] showing preliminary efficacy in Phase 2a): Participants within a given subtype will be randomized 2:1 to receive either talabostat combined with pembrolizumab or talabostat monotherapy.

Phase 1b:

Participants will be observed for dose-limiting toxicity (DLT) during Cycle 1. Three participants will be treated initially with talabostat 0.4 mg plus pembrolizumab:

  • If there are no DLTs in Cycle 1, the dose of talabostat will be escalated to a total daily dose of 0.6 mg in the next cohort of 3 participants.
  • If ≥1 of the 3 original participants has a DLT in Cycle 1, after a discussion between the sponsor and the investigator, either 3 participants (if 1 participant experiences a DLT) or 6 to 9 participants (if 2 or 3 participants experiences a DLT) will be added at the 0.4 mg talabostat dose level. For this expanded 0.4 mg cohort:

    • If none of the participants experience a DLT, consideration will be given to dose escalation to talabostat 0.6 mg plus pembrolizumab
    • If 1/3 of the participants experience a DLT, the Phase 2 can commence
    • If >1/3 of the participants experience a DLT, a discussion will be held between the investigators and sponsors as to how to proceed.

Following dose escalation to talabostat 0.6 mg plus pembrolizumab in 3 participants :

  • If there are no DLTs at this dose level, the Phase 2a can commence.
  • If ≥1/3 participants have a DLT in Cycle 1, after a discussion between the sponsor and the investigator, 6 to 9 participants will be added at the 0.6 mg talabostat total daily dose level; and consideration of an alternate dosing (e.g., split dose) schedule may be given.
  • For this additional cohort of 6 to 9 participants :

    • If \</= 1/3 of the participants experience a DLT, the Phase2a can commence.
    • If >1/3 of the participants experience a DLT, consideration will be given to the use of a 0.4 mg total daily dose of talabostat, or an intermediate dose, plus pembrolizumab in the Phase 2a.
03

Conditions studied

  • Prostate Cancer
  • Neuroendocrine Tumors
  • Small Cell Carcinoma
04

Who can participate

The criteria were revised on the registry on Nov 10, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All participants must satisfy the following inclusion and exclusion criteria to be eligible for entry into the trial.

  1. Participant has evidence of progressive, castration-resistant disease, as defined by Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria.

    a. Participant with de novo small cell prostate cancer are not required to have received androgen deprivation therapy (ADT).

  2. Progression during or following completion of at least 1 for locally advanced or metastatic prostate cancer.
  3. Phases 2a and 2b Only:

    SCNC - Cohort A of Phase 2a only:

    1. Participant has histologic evidence of SCNC either with or a fresh tumor biopsy obtained during screening. Tumor biopsy tissue must be submitted for a central laboratory pathology review; however, enrollment can proceed if SCNC is determined by a local pathology review.
    2. Participant has previously received at least 1 prior line of cytotoxic chemotherapy. Participants who either have refused chemotherapy or are considered unsuitable for chemotherapy may be eligible following discussion with the sponsor.
    3. Must be willing to undergo metastatic tumor biopsy during Screening. Requirement may be waived in participants without safely accessible lesion or for participants with evaluable archival metastatic tumor tissue
    4. Has per version 1.1 (RECIST 1.1) criteria.

    Adenocarcinoma - Cohort B of Phase 2a; randomized population for Phase 2b

    1. Participant has or cytologically confirmed adenocarcinoma of the prostate without small cell neuroendocrine features.
    2. Participants with soft tissue disease must provide a fresh core or excisional biopsy or archival tissue from a site not previously irradiated for central pathology review; however enrollment may proceed if predominant adenocarcinoma without small cell neuroendocrine features is determined by local pathology review.
    3. Has been treated with at least 1 but no more than 2 second generation androgen receptor (AR) pathway target agents (e.g., abiraterone acetate and/or enzalutamide or other next generation agent) and at least 1 regimen/line of taxane containing chemotherapy in the metastatic castration-sensitive prostate cancer (mCSPC) or mCRPC setting. Participants with known actionable mutations should have progressed on applicable standard care targeted therapy or have documented intolerance to or be unsuitable for such therapy.
    4. RECIST 1.1 measurable disease or detectable bone metastases by whole body bone scintigraphy.
  4. Participant has serum testosterone \<50 ng/dL during Screening except for those with de novo small cell prostate cancer.

    a. Participants with treatment-emergent SCNC without a history of bilateral orchiectomy are required to remain on luteinizing hormone-releasing hormone (LHRH) analog during the course of protocol therapy except for participants with de novo small cell prostate cancer.

  5. Participant has (ECOG) performance status of 0-2.
  6. Participant is ≥18 years of age.
  7. Participant's acute toxic effects of previous anticancer therapy have resolved to ≤Grade 1 except for Grade 2-3 peripheral neuropathy or any grade of alopecia.
  8. Participant has adequate baseline organ function, as demonstrated by the following:

    1. Serum creatinine ≤1.5 times institutional (ULN) or calculated >50 mL/min;
    2. Serum albumin ≥2.5 g/dL;
    3. Total ≤1.5 × ULN;
    4. (AST) and alanine aminotransferase (ALT) ≤2.5 × institutional ULN (participants with hepatic metastases must have AST/ALT ≤5 × ULN).
  9. Participant has adequate baseline hematologic function, as demonstrated by the following:

    1. (ANC) ≥1.5 × 109/L.
    2. ≥8 g/dL and no red blood cell transfusions during the prior 14 days.
    3. count ≥100 × 109/L and no platelet transfusions during the prior 14 days.
  10. Male participants and their female partners of must agree and commit to use a barrier throughout the duration of the study until at least 6 months following the last dose of study drug, in addition to their female partners using either an intrauterine device or hormonal contraception and continuing until at least 6 months following the last dose of study drug. This criterion may be waived for male participants who have had a vasectomy >6 months before signing the form.

    Exception: In the United States, female partners of study participants are not required to use contraception as a condition of their partners' eligibility, but female partners with childbearing potential should consider use of effect methods of contraception for the duration of their male partners' study participation and for at least 6 months following the last dose of study medication.

  11. Participant has signed informed consent prior to initiation of any study-specific procedures or treatment.
  12. Participant is able to adhere to the study visit schedule and other protocol requirements, including follow-up for overall survival (OS).

Exclusion criteria

Exclusion Criteria:

  1. Participant has received treatment with >2 cytotoxic chemotherapy regimens for castration-resistant prostate cancer (CRPC). Chemotherapy in the hormone-sensitive setting does not count in this assessment provided the last dose was >6 months before study entry. A change in chemotherapy agents due to intolerance after brief exposure may not count in this assessment, pending review with Medical Monitor.
  2. Participant has received external-beam radiation or another systemic anticancer therapy within 14 days or 5 half-lives, whichever is shorter, prior to study treatment.
  3. Participant has received treatment with an systemic anticancer agent within 14 days prior to study drug administration.
  4. Participant has received prior treatment with an , anti-PD-L1, anti-programmed death ligand 2 (PD-L2) agent or with an agent directed to another co-inhibitory T-cell receptor (e.g., cytotoxic T lymphocyte-associated antigen 4 [CTLA-4], OX-40, CD137) or requires concomitant treatment with DPP4 inhibitors.
  5. Participant has an additional active that may confound the assessment of the study endpoints. If the participant has a past cancer history (active malignancy within 2 years prior to study entry) with substantial potential for recurrence, this must be discussed with the sponsor before study entry. Participants with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin cancer and carcinomas in situ (including transitional cell carcinoma, anal carcinoma, and melanoma in situ).
  6. Participant has cardiovascular disease (e.g., uncontrolled or any Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial infarction, unstable angina or stroke within 6 months prior to study entry, uncontrolled hypertension or clinically significant arrhythmias not controlled by medication).
  7. corrected for heart rate using Bazett's formula (QTcB) >480 msec at Screening.
  8. Participant has uncontrolled, clinically significant pulmonary disease (e.g., , pulmonary hypertension) that in the opinion of the investigator would put the participant at significant risk for pulmonary complications during the study.
  9. Participant has brain or that are symptomatic and progressive on imaging. Participants with a history of central nervous system (CNS) must have received appropriate treatment. Central nervous system imaging is not required prior to study entry unless there is a history of CNS involvement or clinical suspicion of CNS involvement. Imaging of participants with a prior history of should be compared to prior imaging to discern disease progression.
  10. Participant has an active disease or Grade ≥3 non-infectious pneumonitis that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, , or drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) or treatment with drugs (e.g., neomercazol, carbimazole) that function to decrease the generation of thyroid hormone by a hyperfunctioning thyroid gland (e.g., in Graves' disease) is not considered a form of systemic treatment of an autoimmune disease.
  11. Participant has a diagnosis of immunodeficiency or is receiving systemic steroid therapy at a prednisone equivalent dose of >10 mg daily for at least 1 week or other form of immunosuppressive therapy within 7 days prior to Cycle 1 Day 1 (C1D1).
  12. Participant has uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, suspected or active Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, disseminated intravascular coagulation, or psychiatric illness/social situations that would limit compliance with study requirements.
  13. Participant has known positive status for , active or chronic , or . Screening is not required.
  14. Participant has any medical condition which, in the opinion of the investigator, places the participant at an unacceptably high risk for toxicity.
  15. Any dysphagia, odynophagia, esophageal dysmotility or stricture, known gastro-intestinal (GI) malabsorption syndrome, or intractable diarrhea that may significantly alter the absorption of orally administered study drug.
  16. Participants with history of symptomatic orthostatic hypotension within 3 months prior to enrollment. Orthostatic hypotension is defined as a drop in systolic blood pressure (BP) of ≥ 20 mmHg or diastolic BP of ≥ 10 mmHg with assumption of an upright posture.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    Phase 1B: Talabostat 0.4 mg QD + Pembrolizumab 200 mg

    Participants will receive the combination of talabostat 0.4 mg QD orally on Days 1 to 14 of a 21-day cycle plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.

    Drug: Talabostat · Drug: Pembrolizumab

  • Experimental
    Phase 1B: Talabostat 0.6 mg QD + Pembrolizumab 200 mg

    Participants will receive the combination of talabostat 0.6 mg QD orally on Days 1 to 14 of a 21-day cycle plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.

    Drug: Talabostat · Drug: Pembrolizumab

  • Experimental
    Phase 1B: Talabostat 0.6 mg TDD + Pembrolizumab 200 mg

    Participants will receive the combination of talabostat 0.3 mg twice daily (BID) (at a total daily dose \[TDD\] of 0.6 mg) orally on Days 1 to 14 of a 21-day cycle plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.

    Drug: Talabostat · Drug: Pembrolizumab

  • Experimental
    Phase 2A (SCNC): Talabostat + Pembrolizumab 200 mg

    Participants with SCNC will receive the combination of talabostat 0.6 mg QD orally on Days 1 to 14 a 21-day cycle plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.

    Drug: Talabostat · Drug: Pembrolizumab

  • Experimental
    Phase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg

    Participants with adenocarcinoma will receive the combination of talabostat 0.6 mg QD orally on Days 1 to 14 a 21-day cycle plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.

    Drug: Talabostat · Drug: Pembrolizumab

  • Experimental
    Phase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg

    Participants with adenocarcinoma will receive the combination of talabostat 0.6 mg QD orally on Days 1 to 14 a 21-day cycle plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.

    Drug: Talabostat · Drug: Pembrolizumab

  • Experimental
    Phase 2B (Adenocarcinoma): Talabostat Monotherapy

    Participants with adenocarcinoma will receive talabostat 0.6 mg QD orally on Days 1 to 14 a 21-day cycle. There will be a 7-day rest period following the last dose of talabostat and Day 1 of the subsequent cycle.

    Drug: Talabostat

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 2a: Composite Response Rate (CRR)

    CRR was defined as the percentage of participants who achieved 1 or more of the following: objective response by Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) criteria; ≥50% decline from baseline in serum Prostate-Specific Antigen (PSA); or Circulating Tumor Cell (CTC) conversion from ≥5/7.5 milliliters (mL) to \<5/7.5 mL per Veridex assay. Objective response rate was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) among participants with evaluable lesions by RECIST v1.1. CR=disappearance of all target and non-target lesions and no new lesions. PR = ≥30% decrease in the sum of diameters (SOD) of target lesions compared to baseline and no new non-target lesion.

    Time frame: Up to approximately 4 years and 4 months

  2. Phase 2b: Objective Response Rate (ORR)

    The ORR was defined as the percentage of participants with a confirmed CR or PR among participants with evaluable lesions by RECIST v1.1. CR=disappearance of all target and non-target lesions and no new lesions. PR = ≥30% decrease in the sum of the diameters of target lesions compared to baseline and no new non-target lesion.

    Time frame: Up to approximately 4 years and 4 months

Secondary outcomes

  1. Phase 2a: Radiographic Progression-free Survival (rPFS)

    The rPFS was defined as the time from the first dose to the date measurement criteria are first met for disease progression (PD) by RECIST 1.1/Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria or death from any cause, whichever occurred first. PD for soft tissue was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 millimeters (mm) in the SOD of target lesions; progression of non-target lesions; the appearance of one or more new lesions according to RECIST v1.1. PD for bone lesions was defined as 2 or more new lesions compared to baseline followed by a confirmatory bone scan at least 6 weeks later according to the PCWG3 criteria. Kaplan-Meier (KM) estimate was used to determine the median rPFS.

    Time frame: Up to approximately 6 years 2 months

  2. Phase 2a: Prostate Specific Antigen (PSA) Progression-free Survival (PFS)

    The PSA PFS was defined as the time from the date of first dose to the date measurement criteria were first met for PSA progression by PCWG3 criteria or death from any cause, whichever occurred first. PSA progression was defined as a PSA increase that was ≥ 25% and ≥ 2 nanograms (ng)/mL above the baseline or the nadir, which was confirmed by a second value ≥ 3 weeks later. KM estimate was used to determine the median PSA PFS.

    Time frame: Up to approximately 6 years and 2 months

  3. Phase 2a: Overall Survival (OS)

    The OS was defined as the difference in days between the date of death and the first date of study treatment (+1 day).

    Time frame: Up to approximately 6 years and 2 months

  4. Phase 2a: Duration of Response (DOR)

    The DOR was defined as the time from the first objective response (CR or PR) to the first documented PD per RECIST v1.1 or death from any cause, whichever occurred first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD: at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: Up to approximately 6 years and 2 months

  5. Phase 2a: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant participating in a clinical investigation, whether or not considered related to treatment. A TEAE was defined as an AE occurring on / after the date of first dose of talabostat/pembrolizumab and within 30 days of the last dose of talabostat/pembrolizumab..

    Time frame: From first dose of study drug up to approximately 6 years and 2 months

  6. Phase 2a: ≥50% Decline in PSA Value From Baseline (PSA50) Duration of Response (PSA50 DOR)

    The PSA50 DOR was defined as the time interval between the first date when PSA declined 50% or more from baseline and the date on which PSA progression was confirmed or death from any cause, whichever occurred first. PSA progression by PCWG3 criteria was defined as a PSA increase that was ≥ 25% and ≥ 2 ng/mL above the baseline or the nadir.

    Time frame: Up to approximately 6 years and 2 months

  7. Phase 2a: Duration of Stable Disease

    Duration of stable disease by RECIST v1.1 was defined as the time interval between the first date when the criteria for stable disease were met and the first date on which objective progression was documented or death from any cause, whichever occurs first. Objective progression: at least a 20% increase in the SOD of target lesion. Stable disease was defined as \<30% decrease and \<20% increase in the size of target lesions, persistence of non-target lesions, and no new lesions.

    Time frame: Up to approximately 6 years and 2 months

  8. Phase 2b: Number of Participants With PSA Decline From Baseline of at Least 50%

    Time frame: Up to approximately 6 years and 2 months

  9. Phase 2b: CRR

    CRR was defined as the percentage of participants who achieved 1 or more of the following: objective response by RECIST v1.1 criteria; ≥50% decline from baseline in serum PSA, or CTC conversion from ≥5/7.5 mL to \<5/7.5 mL per Veridex assay. Objective response rate was defined as the percentage of participants with a confirmed CR or PR among participants with evaluable lesions by RECIST v1.1. CR=disappearance of all target and non-target lesions and no new lesions. PR = ≥30% decrease in the SOD of target lesions compared to baseline and no new non-target lesion.

    Time frame: Up to approximately 6 years and 2 months

  10. Phase 2b: rPFS

    The rPFS was defined as the time from the first dose to the date measurement criteria were first met for PD by RECIST 1.1/PCWG3 criteria or death from any cause, whichever occurred first. PD for soft tissue was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 mm in the SOD of target lesions; progression of non-target lesions; the appearance of one or more new lesions according to RECIST v1.1. PD for bone lesions was defined as 2 or more new lesions compared to baseline followed by a confirmatory bone scan at least 6 weeks later according to the PCWG3 criteria. KM estimate was used to determine the median rPFS.

    Time frame: Up to approximately 6 years and 2 months

  11. Phase 2b: PSA PFS

    The PSA PFS was defined as the time from the date of first dose to the date measurement criteria were first met for PSA progression by PCWG3 criteria or death from any cause, whichever occurred first. PSA progression was defined as a PSA increase that was ≥ 25% and ≥ 2 ng/mL above the baseline or the nadir. KM estimate was used to determine the median PSA PFS.

    Time frame: Up to approximately 6 years and 2 months

  12. Phase 2b: OS

    The OS was defined as the difference in days between the date of death and the first date of study treatment (+1 day).

    Time frame: Up to approximately 6 years and 2 months

  13. Phase 2b: DOR

    The DOR was defined as the time from the first objective response (CR or PR) to the first documented PD per RECIST v1.1 or death from any cause, whichever occurred first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD: at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: Up to approximately 6 years and 2 months

  14. Phase 2b: PSA50 DOR

    The PSA50 DOR was defined as the time interval between the first date when PSA declined 50% or more from baseline and the date on which PSA progression was confirmed or death from any cause, whichever occurred first. PSA progression by PCWG3 criteria was defined as a PSA increase that was ≥ 25% and ≥ 2 ng/mL above the baseline or the nadir.

    Time frame: Up to approximately 6 years and 2 months

  15. Phase 2b: Duration of Stable Disease

    Duration of stable disease by RECIST v1.1 was defined as the time interval between the first date when the criteria for stable disease were met and the first date on which objective progression was documented or death from any cause, whichever occurs first. Objective progression: at least a 20% increase in the SOD of target lesion. Stable disease was defined as \<30% decrease and \<20% increase in the size of target lesions, persistence of non-target lesions, and no new lesions.

    Time frame: Up to approximately 6 years and 2 months

  16. Phase 2a: Plasma Concentration of Talabostat

    Time frame: Up to approximately 6 years and 2 months

  17. Phase 2a: Concentration of Plasma Cytokines

    Time frame: Up to approximately 6 years and 2 months

07

Results

Posted Nov 10, 2026

Participant flow

The study was conducted in United States from 10-Jun-2019 to 31-Aug-2025.

Participant flow — Overall Study
MilestonePhase 1B: Talabostat 0.4 mg QD + Pembrolizumab 200 mgPhase 1B: Talabostat 0.6 mg QD + Pembrolizumab 200 mgPhase 1B: Talabostat 0.6 mg TDD + Pembrolizumab 200 mgPhase 2A (SCNC): Talabostat + Pembrolizumab 200 mgPhase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mgPhase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mgPhase 2B (Adenocarcinoma): Talabostat Monotherapy
Started337344253
Completed0005210
Not completed337294043
Withdrew: Death325151902
Withdrew: Withdrawal by subject01141211
Withdrew: Protocol-defined disease progression0010300
Withdrew: Lost to follow-up0002200
Withdrew: Other than specified0008330
Withdrew: Adverse event0000100

Outcome measures

PrimaryPhase 2a: Composite Response Rate (CRR)

CRR was defined as the percentage of participants who achieved 1 or more of the following: objective response by Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) criteria; ≥50% decline from baseline in serum Prostate-Specific Antigen (PSA); or Circulating Tumor Cell (CTC) conversion from ≥5/7.5 milliliters (mL) to \<5/7.5 mL per Veridex assay. Objective response rate was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) among participants with evaluable lesions by RECIST v1.1. CR=disappearance of all target and non-target lesions and no new lesions. PR = ≥30% decrease in the sum of diameters (SOD) of target lesions compared to baseline and no new non-target lesion.

Time frame:
Up to approximately 4 years and 4 months
Reported as:
Number · percentage of participants
Phase 2a: Composite Response Rate (CRR)
percentage of participantsPhase 2A (SCNC): Talabostat + Pembrolizumab 200 mgPhase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg
Phase 2a: Composite Response Rate (CRR)20.0 (7.71 to 38.57)18.2 (6.98 to 35.46)
PrimaryPhase 2b: Objective Response Rate (ORR)

The ORR was defined as the percentage of participants with a confirmed CR or PR among participants with evaluable lesions by RECIST v1.1. CR=disappearance of all target and non-target lesions and no new lesions. PR = ≥30% decrease in the sum of the diameters of target lesions compared to baseline and no new non-target lesion.

Time frame:
Up to approximately 4 years and 4 months
Reported as:
Number · percentage of participants
Phase 2b: Objective Response Rate (ORR)
percentage of participantsPhase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mgPhase 2B (Adenocarcinoma): Talabostat Monotherapy
Phase 2b: Objective Response Rate (ORR)0.0 (0.00 to 70.76)NA (NA to NA)
SecondaryPhase 2a: Radiographic Progression-free Survival (rPFS)

The rPFS was defined as the time from the first dose to the date measurement criteria are first met for disease progression (PD) by RECIST 1.1/Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria or death from any cause, whichever occurred first. PD for soft tissue was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 millimeters (mm) in the SOD of target lesions; progression of non-target lesions; the appearance of one or more new lesions according to RECIST v1.1. PD for bone lesions was defined as 2 or more new lesions compared to baseline followed by a confirmatory bone scan at least 6 weeks later according to the PCWG3 criteria. Kaplan-Meier (KM) estimate was used to determine the median rPFS.

Time frame:
Up to approximately 6 years 2 months
Reported as:
Median · months
Phase 2a: Radiographic Progression-free Survival (rPFS)
monthsPhase 2A (SCNC): Talabostat + Pembrolizumab 200 mgPhase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg
Phase 2a: Radiographic Progression-free Survival (rPFS)2.07 (1.91 to 4.17)1.87 (1.41 to 2.20)
SecondaryPhase 2a: Prostate Specific Antigen (PSA) Progression-free Survival (PFS)

The PSA PFS was defined as the time from the date of first dose to the date measurement criteria were first met for PSA progression by PCWG3 criteria or death from any cause, whichever occurred first. PSA progression was defined as a PSA increase that was ≥ 25% and ≥ 2 nanograms (ng)/mL above the baseline or the nadir, which was confirmed by a second value ≥ 3 weeks later. KM estimate was used to determine the median PSA PFS.

Time frame:
Up to approximately 6 years and 2 months
Reported as:
Median · months
Phase 2a: Prostate Specific Antigen (PSA) Progression-free Survival (PFS)
monthsPhase 2A (SCNC): Talabostat + Pembrolizumab 200 mgPhase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg
Phase 2a: Prostate Specific Antigen (PSA) Progression-free Survival (PFS)10.94 (3.55 to 12.22)2.79 (1.45 to 7.98)
SecondaryPhase 2a: Overall Survival (OS)

The OS was defined as the difference in days between the date of death and the first date of study treatment (+1 day).

Time frame:
Up to approximately 6 years and 2 months
Reported as:
Median · months
Phase 2a: Overall Survival (OS)
monthsPhase 2A (SCNC): Talabostat + Pembrolizumab 200 mgPhase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg
Phase 2a: Overall Survival (OS)13.67 (7.00 to NA)12.12 (5.45 to 16.36)
SecondaryPhase 2a: Duration of Response (DOR)

The DOR was defined as the time from the first objective response (CR or PR) to the first documented PD per RECIST v1.1 or death from any cause, whichever occurred first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD: at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
Up to approximately 6 years and 2 months
Reported as:
Median · months
Phase 2a: Duration of Response (DOR)
monthsPhase 2A (SCNC): Talabostat + Pembrolizumab 200 mgPhase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg
Phase 2a: Duration of Response (DOR)9.03 (6.21 to NA)NA (6.47 to NA)
SecondaryPhase 2a: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant participating in a clinical investigation, whether or not considered related to treatment. A TEAE was defined as an AE occurring on / after the date of first dose of talabostat/pembrolizumab and within 30 days of the last dose of talabostat/pembrolizumab..

Time frame:
From first dose of study drug up to approximately 6 years and 2 months
Reported as:
Count of participants · Participants
Phase 2a: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsPhase 2A (SCNC): Talabostat + Pembrolizumab 200 mgPhase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg
Phase 2a: Number of Participants With Treatment-emergent Adverse Events (TEAEs)3442
SecondaryPhase 2a: ≥50% Decline in PSA Value From Baseline (PSA50) Duration of Response (PSA50 DOR)

The PSA50 DOR was defined as the time interval between the first date when PSA declined 50% or more from baseline and the date on which PSA progression was confirmed or death from any cause, whichever occurred first. PSA progression by PCWG3 criteria was defined as a PSA increase that was ≥ 25% and ≥ 2 ng/mL above the baseline or the nadir.

Time frame:
Up to approximately 6 years and 2 months
Reported as:
Median · months
Phase 2a: ≥50% Decline in PSA Value From Baseline (PSA50) Duration of Response (PSA50 DOR)
monthsPhase 2A (SCNC): Talabostat + Pembrolizumab 200 mgPhase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg
Phase 2a: ≥50% Decline in PSA Value From Baseline (PSA50) Duration of Response (PSA50 DOR)14.75 (6.37 to NA)NA (1.38 to NA)
SecondaryPhase 2a: Duration of Stable Disease

Duration of stable disease by RECIST v1.1 was defined as the time interval between the first date when the criteria for stable disease were met and the first date on which objective progression was documented or death from any cause, whichever occurs first. Objective progression: at least a 20% increase in the SOD of target lesion. Stable disease was defined as \<30% decrease and \<20% increase in the size of target lesions, persistence of non-target lesions, and no new lesions.

Time frame:
Up to approximately 6 years and 2 months
Reported as:
Median · months
Phase 2a: Duration of Stable Disease
monthsPhase 2A (SCNC): Talabostat + Pembrolizumab 200 mgPhase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg
Phase 2a: Duration of Stable Disease3.12 (1.87 to NA)6.31 (2.33 to NA)
SecondaryPhase 2b: Number of Participants With PSA Decline From Baseline of at Least 50%
Time frame:
Up to approximately 6 years and 2 months
Reported as:
Count of participants · Participants
Phase 2b: Number of Participants With PSA Decline From Baseline of at Least 50%
ParticipantsPhase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mgPhase 2B (Adenocarcinoma): Talabostat Monotherapy
Phase 2b: Number of Participants With PSA Decline From Baseline of at Least 50%00
SecondaryPhase 2b: CRR

CRR was defined as the percentage of participants who achieved 1 or more of the following: objective response by RECIST v1.1 criteria; ≥50% decline from baseline in serum PSA, or CTC conversion from ≥5/7.5 mL to \<5/7.5 mL per Veridex assay. Objective response rate was defined as the percentage of participants with a confirmed CR or PR among participants with evaluable lesions by RECIST v1.1. CR=disappearance of all target and non-target lesions and no new lesions. PR = ≥30% decrease in the SOD of target lesions compared to baseline and no new non-target lesion.

Time frame:
Up to approximately 6 years and 2 months
Reported as:
Number · percentage of participants
Phase 2b: CRR
percentage of participantsPhase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mgPhase 2B (Adenocarcinoma): Talabostat Monotherapy
Phase 2b: CRR0.0 (0.00 to 52.18)0.0 (0.00 to 84.19)
SecondaryPhase 2b: rPFS

The rPFS was defined as the time from the first dose to the date measurement criteria were first met for PD by RECIST 1.1/PCWG3 criteria or death from any cause, whichever occurred first. PD for soft tissue was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on study, including baseline, and an absolute increase of at least 5 mm in the SOD of target lesions; progression of non-target lesions; the appearance of one or more new lesions according to RECIST v1.1. PD for bone lesions was defined as 2 or more new lesions compared to baseline followed by a confirmatory bone scan at least 6 weeks later according to the PCWG3 criteria. KM estimate was used to determine the median rPFS.

Time frame:
Up to approximately 6 years and 2 months
Reported as:
Median · months
Phase 2b: rPFS
monthsPhase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mgPhase 2B (Adenocarcinoma): Talabostat Monotherapy
Phase 2b: rPFS1.38 (0.72 to NA)5.75 (0.95 to NA)
SecondaryPhase 2b: PSA PFS

The PSA PFS was defined as the time from the date of first dose to the date measurement criteria were first met for PSA progression by PCWG3 criteria or death from any cause, whichever occurred first. PSA progression was defined as a PSA increase that was ≥ 25% and ≥ 2 ng/mL above the baseline or the nadir. KM estimate was used to determine the median PSA PFS.

Time frame:
Up to approximately 6 years and 2 months
Reported as:
Median · percentage of participants
Phase 2b: PSA PFS
percentage of participantsPhase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mgPhase 2B (Adenocarcinoma): Talabostat Monotherapy
Phase 2b: PSA PFS1.41 (0.72 to NA)5.75 (0.95 to NA)
SecondaryPhase 2b: OS

The OS was defined as the difference in days between the date of death and the first date of study treatment (+1 day).

Time frame:
Up to approximately 6 years and 2 months
Reported as:
Median · months
Phase 2b: OS
monthsPhase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mgPhase 2B (Adenocarcinoma): Talabostat Monotherapy
Phase 2b: OSNA (NA to NA)7.31 (4.07 to NA)
SecondaryPhase 2b: DOR

The DOR was defined as the time from the first objective response (CR or PR) to the first documented PD per RECIST v1.1 or death from any cause, whichever occurred first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. PD: at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
Up to approximately 6 years and 2 months
Reported as:
Median · months
Phase 2b: DOR
monthsPhase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mgPhase 2B (Adenocarcinoma): Talabostat Monotherapy
Phase 2b: DORNA (NA to NA)NA (NA to NA)
SecondaryPhase 2b: PSA50 DOR

The PSA50 DOR was defined as the time interval between the first date when PSA declined 50% or more from baseline and the date on which PSA progression was confirmed or death from any cause, whichever occurred first. PSA progression by PCWG3 criteria was defined as a PSA increase that was ≥ 25% and ≥ 2 ng/mL above the baseline or the nadir.

Time frame:
Up to approximately 6 years and 2 months
Reported as:
Median · months
Phase 2b: PSA50 DOR
monthsPhase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mgPhase 2B (Adenocarcinoma): Talabostat Monotherapy
Phase 2b: PSA50 DORNA (NA to NA)NA (NA to NA)
SecondaryPhase 2b: Duration of Stable Disease

Duration of stable disease by RECIST v1.1 was defined as the time interval between the first date when the criteria for stable disease were met and the first date on which objective progression was documented or death from any cause, whichever occurs first. Objective progression: at least a 20% increase in the SOD of target lesion. Stable disease was defined as \<30% decrease and \<20% increase in the size of target lesions, persistence of non-target lesions, and no new lesions.

Time frame:
Up to approximately 6 years and 2 months
Reported as:
Median · months
Phase 2b: Duration of Stable Disease
monthsPhase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mgPhase 2B (Adenocarcinoma): Talabostat Monotherapy
Phase 2b: Duration of Stable DiseaseNA (2.20 to NA)NA (NA to NA)
SecondaryPhase 2a: Plasma Concentration of Talabostat
Time frame:
Up to approximately 6 years and 2 months

No measurements were reported for this outcome.

SecondaryPhase 2a: Concentration of Plasma Cytokines
Time frame:
Up to approximately 6 years and 2 months

No measurements were reported for this outcome.

Adverse events

Collected over From first dose of study drug up to approximately 6 years and 2 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1B: Talabostat 0.4 mg QD + Pembrolizumab 200 mg3/3 (100%)2/3 (66.7%)3/3 (100%)
Phase 1B: Talabostat 0.6 mg QD + Pembrolizumab 200 mg2/3 (66.7%)1/3 (33.3%)3/3 (100%)
Phase 1B: Talabostat 0.6 mg TDD + Pembrolizumab 200 mg5/7 (71.4%)4/7 (57.1%)7/7 (100%)
Phase 2A (SCNC): Talabostat + Pembrolizumab18/34 (52.9%)13/34 (38.2%)34/34 (100%)
Phase 2A (Adenocarcinoma): Talabostat + Pembrolizumab20/42 (47.6%)14/42 (33.3%)42/42 (100%)
Phase 2B (Adenocarcinoma): Talabostat + Pembrolizumab0/5 (0%)1/5 (20%)5/5 (100%)
Phase 2B (Adenocarcinoma): Talabostat Monotherapy2/3 (66.7%)1/3 (33.3%)3/3 (100%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventPhase 1B: Talabostat 0.4 mg QD + Pembrolizumab 200 mgPhase 1B: Talabostat 0.6 mg QD + Pembrolizumab 200 mgPhase 1B: Talabostat 0.6 mg TDD + Pembrolizumab 200 mgPhase 2A (SCNC): Talabostat + PembrolizumabPhase 2A (Adenocarcinoma): Talabostat + PembrolizumabPhase 2B (Adenocarcinoma): Talabostat + PembrolizumabPhase 2B (Adenocarcinoma): Talabostat Monotherapy
Urinary Tract InfectionInfections and infestations1/30/30/72/340/420/51/3
SepsisInfections and infestations1/30/30/70/340/420/50/3
AcidosisMetabolism and nutrition disorders0/31/30/70/340/420/50/3
AnaemiaBlood and lymphatic system disorders1/30/30/70/341/420/50/3
Malignant Neoplasm ProgressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/32/70/341/420/50/3
Acute Kidney InjuryRenal and urinary disorders0/30/30/73/340/421/50/3
Large Intestine PerforationGastrointestinal disorders0/30/31/70/340/420/50/3
PneumonitisRespiratory, thoracic and mediastinal disorders0/30/31/70/340/420/50/3
Back PainMusculoskeletal and connective tissue disorders0/30/31/71/341/420/50/3
Abdominal PainGastrointestinal disorders0/30/31/71/341/420/50/3
Most frequent other events
Showing 10 of 180
Most frequent other events
EventPhase 1B: Talabostat 0.4 mg QD + Pembrolizumab 200 mgPhase 1B: Talabostat 0.6 mg QD + Pembrolizumab 200 mgPhase 1B: Talabostat 0.6 mg TDD + Pembrolizumab 200 mgPhase 2A (SCNC): Talabostat + PembrolizumabPhase 2A (Adenocarcinoma): Talabostat + PembrolizumabPhase 2B (Adenocarcinoma): Talabostat + PembrolizumabPhase 2B (Adenocarcinoma): Talabostat Monotherapy
FatigueGeneral disorders3/31/33/716/3424/421/50/3
HypocalcaemiaMetabolism and nutrition disorders3/30/31/72/348/420/51/3
ConstipationGastrointestinal disorders0/31/34/710/348/422/52/3
Oedema PeripheralGeneral disorders2/32/30/712/345/422/50/3
MyalgiaMusculoskeletal and connective tissue disorders1/32/31/73/345/421/50/3
DizzinessNervous system disorders0/32/30/77/347/421/50/3
Neuropathy PeripheralNervous system disorders2/30/31/71/340/420/50/3
Blood Alkaline Phosphatase IncreasedInvestigations2/30/30/74/3411/420/50/3
AnaemiaBlood and lymphatic system disorders2/30/32/75/3412/423/52/3
Increased Tendency To BruiseBlood and lymphatic system disorders2/30/30/70/340/420/50/3

Baseline characteristics

The safety population consisted of all participants who received any dose of talabostat or pembrolizumab during any phase of the study.

Age, Categorical
Age, Categorical(Participants)Phase 1B: Talabostat 0.4 mg QD + Pembrolizumab 200 mgPhase 1B: Talabostat 0.6 mg QD + Pembrolizumab 200 mgPhase 1B: Talabostat 0.6 mg TDD + Pembrolizumab 200 mgPhase 2A (SCNC): Talabostat + PembrolizumabPhase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mgPhase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mgPhase 2B (Adenocarcinoma): Talabostat MonotherapyTotal
<=18 years00000000
Between 18 and 65 years11210102127
>=65 years22524323270
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1B: Talabostat 0.4 mg QD + Pembrolizumab 200 mgPhase 1B: Talabostat 0.6 mg QD + Pembrolizumab 200 mgPhase 1B: Talabostat 0.6 mg TDD + Pembrolizumab 200 mgPhase 2A (SCNC): Talabostat + PembrolizumabPhase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mgPhase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mgPhase 2B (Adenocarcinoma): Talabostat MonotherapyTotal
Female00000000
Male33734425397
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1B: Talabostat 0.4 mg QD + Pembrolizumab 200 mgPhase 1B: Talabostat 0.6 mg QD + Pembrolizumab 200 mgPhase 1B: Talabostat 0.6 mg TDD + Pembrolizumab 200 mgPhase 2A (SCNC): Talabostat + PembrolizumabPhase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mgPhase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mgPhase 2B (Adenocarcinoma): Talabostat MonotherapyTotal
Hispanic or Latino00020215
Not Hispanic or Latino23732403289
Unknown or Not Reported10002003
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1B: Talabostat 0.4 mg QD + Pembrolizumab 200 mgPhase 1B: Talabostat 0.6 mg QD + Pembrolizumab 200 mgPhase 1B: Talabostat 0.6 mg TDD + Pembrolizumab 200 mgPhase 2A (SCNC): Talabostat + PembrolizumabPhase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mgPhase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mgPhase 2B (Adenocarcinoma): Talabostat MonotherapyTotal
American Indian or Alaska Native00000000
Asian00022206
Native Hawaiian or Other Pacific Islander00000000
Black or African American00123006
White13627352377
More than one race00000101
Unknown or Not Reported20032007
08

Study locations

12 sites
  • University of California San Francisco (UCSF)
    San Francisco, California 94158, United States
  • BioXcel Clinical Research Site
    Denver, Colorado 80211, United States
  • Yale University
    New Haven, Connecticut 06510, United States
  • Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • BioXcel Clinical Research Site
    Detroit, Michigan 48201, United States
  • Center for Advanced Medicine / R.J. Zuckerberg Cancer Center (Northwell Health Cancer Institute)
    Lake Success, New York 11042, United States
  • Weill Cornell Medicine New York
    New York, New York 10021, United States
  • White Plains Hospital Center for Cancer Care
    White Plains, New York 10601, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • BioXcel Clinical Research Site
    Glasgow, England G12 0YN, United Kingdom
  • BioXcel Clinical Research Site
    London, Great Britain W1T 7HA, United Kingdom
  • BioXcel Clinical Research Site
    Sutton, Surrey SM2 5NG, United Kingdom
09

References and documents

Publications

  • Aggarwal R, Zhang J, Monk P, Zhu X, Jones R, Linch M, Costin D, de Bono J, Karsh LI, Petrylak DP, Zhang L, Deshpande R, Borderies P, Huang J, O'Neill V, Donkor M, Tagawa S. Phase 2 study of talabostat, a small molecule inhibitor of dipeptidyl peptidases (DPP), administered in combination with pembrolizumab in patients with small cell neuroendocrine prostate cancer. J Immunother Cancer. 2026 May 11;14(5):e014242. doi: 10.1136/jitc-2025-014242. PubMed 42114950 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Oct 2023, 52 months.

Results were first posted in Nov 2026, 3 years after primary completion.

Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's 52 months is close to that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 88.

Start moved once since we started tracking on Sep 25, 2026: Feb 2019 → Jun 2019, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2019
First posted
Apr 10, 2019
StartActual
Jun 10, 2019was Feb 2019
Primary completionActual
Oct 31, 2023
CompletionActual
Aug 31, 2025
Results first posted
Nov 10, 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 10, 2026
Start date
Feb 12, 2019→Jun 10, 2019
Nov 10, 2026
Enrollment
98→97
Nov 10, 2026
Eligibility
22 inclusion criteria edited; 15 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedAll patientsparticipants must satisfy the following inclusion and exclusion criteria to be eligible for entry into the trial.
  • EditedPatientParticipant has evidence of progressive, metastatic castration-resistant disease, as defined by Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria.
  • EditedPatientsParticipant with de novo small cell prostate cancer are not required to have received androgen deprivation therapy (ADT).
  • EditedPatientParticipant has histologic evidence of SCNC either with archival tissue or a fresh tumor biopsy obtained during screening. Tumor biopsy tissue must be submitted for a central laboratory pathology review; however, enrollment can proceed if SCNC is determined by a local pathology review.
  • EditedPatientParticipant has previously received at least 1 prior line of cytotoxic chemotherapy. PatientsParticipants who either have refused chemotherapy or are considered unsuitable for chemotherapy may be eligible following discussion with the sponsor.
  • EditedMust be willing to undergo metastatic tumor biopsy during Screening. Requirement may be waived in patientsparticipants without safely accessible lesion or for patientsparticipants with evaluable archival metastatic tumor tissue
  • EditedHas measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) criteria.
  • EditedPatientParticipant has histologically or cytologically confirmed adenocarcinoma of the prostate without small cell neuroendocrine features.
  • EditedPatientsParticipants with soft tissue disease must provide a fresh core or excisional biopsy or archival tissue from a site not previously irradiated for central pathology review; however enrollment may proceed if predominant adenocarcinoma without small cell neuroendocrine features is determined by local pathology review.
  • EditedHas been treated with at least 1 but no more than 2 second generation androgen receptor (AR) pathway target agents (e.g., abiraterone acetate and/or enzalutamide or other next generation agent) and at least 1 regimen/line of taxane containing chemotherapy in the metastatic castration-sensitive prostate cancer (mCSPC) or mCRPC setting. PatientsParticipants with known actionable mutations should have progressed on applicable standard care targeted therapy or have documented intolerance to or be unsuitable for such therapy.
  • EditedPatientParticipant has serum testosterone <50 ng/dL during Screening except for those with de novo small cell prostate cancer.
  • EditedPatientsParticipants with treatment-emergent SCNC without a history of bilateral orchiectomy are required to remain on luteinizing hormone-releasing hormone (LHRH) analog during the course of protocol therapy except for patientsparticipants with de novo small cell prostate cancer.
  • EditedPatientParticipant has Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
  • EditedPatientParticipant is ≥18 years of age.
  • EditedPatientParticipant's acute toxic effects of previous anticancer therapy have resolved to ≤Grade 1 except for Grade 2-3 peripheral neuropathy or any grade of alopecia.
  • EditedPatientParticipant has adequate baseline organ function, as demonstrated by the following:
  • EditedAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × institutional ULN (patientsparticipants with hepatic metastases must have AST/ALT ≤5 × ULN).
  • EditedPatientParticipant has adequate baseline hematologic function, as demonstrated by the following:
  • EditedMale patientsparticipants and their female partners of childbearing potential must agree and commit to use a barrier contraception throughout the duration of the study until at least 6 months following the last dose of study drug, in addition to their female partners using either an intrauterine device or hormonal contraception and continuing until at least 6 months following the last dose of study drug. This criterion may be waived for male patientsparticipants who have had a vasectomy >6 months before signing the informed consent form.
  • EditedException: In the United States, female partners of study participants are not required to use contraception as a condition of their partners' eligibility, but female partners with child bearingchildbearing potential should consider use of effect methods of contraception for the duration of their male partners' study participation and for at least 6 months following the last dose of study medication.
  • EditedPatientParticipant has signed informed consent prior to initiation of any study-specific procedures or treatment.
  • EditedPatientParticipant is able to adhere to the study visit schedule and other protocol requirements, including follow-up for overall survival (OS).
Exclusion criteria
  • EditedPatientParticipant has received treatment with >2 cytotoxic chemotherapy regimens for castration-resistant prostate cancer (CRPC). Chemotherapy in the hormone-sensitive setting does not count in this assessment provided the last dose was >6 months before study entry. A change in chemotherapy agents due to intolerance after brief exposure may not count in this assessment, pending review with Medical Monitor.
  • EditedPatientParticipant has received external-beam radiation or another systemic anticancer therapy within 14 days or 5 half-lives, whichever is shorter, prior to study treatment.
  • EditedPatientParticipant has received treatment with an investigational systemic anticancer agent within 14 days prior to study drug administration.
  • EditedPatientParticipant has received prior treatment with an anti-PD-1, anti-PD-L1, anti-programmed death ligand 2 (PD-L2) agent or with an agent directed to another co-inhibitory T-cell receptor (e.g., cytotoxic T lymphocyte-associated antigen 4 [CTLA-4], OX-40, CD137) or requires concomitant treatment with DPP4 inhibitors.
  • EditedPatientParticipant has an additional active malignancy that may confound the assessment of the study endpoints. If the patientparticipant has a past cancer history (active malignancy within 2 years prior to study entry) with substantial potential for recurrence, this must be discussed with the sponsor before study entry. PatientsParticipants with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin cancer and carcinomas in situ (including transitional cell carcinoma, anal carcinoma, and melanoma in situ).
  • EditedPatientParticipant has clinically significant cardiovascular disease (e.g., uncontrolled or any New York Heart Association Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial infarction, unstable angina or stroke within 6 months prior to study entry, uncontrolled hypertension or clinically significant arrhythmias not controlled by medication).
  • EditedPatientParticipant has uncontrolled, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease, pulmonary hypertension) that in the opinion of the investigator would put the patientparticipant at significant risk for pulmonary complications during the study.
  • EditedPatientParticipant has brain or leptomeningeal metastases that are symptomatic and progressive on imaging. PatientsParticipants with a history of central nervous system (CNS) metastases must have received appropriate treatment. Central nervous system imaging is not required prior to study entry unless there is a history of CNS involvement or clinical suspicion of CNS involvement. Imaging of patientsparticipants with a prior history of CNS metastases should be compared to prior imaging to discern disease progression.
  • EditedPatientParticipant has an active autoimmune disease or Grade ≥3 non-infectious pneumonitis that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) or treatment with drugs (e.g., neomercazol, carbimazole) that function to decrease the generation of thyroid hormone by a hyperfunctioning thyroid gland (e.g., in Graves' disease) is not considered a form of systemic treatment of an autoimmune disease.
  • EditedPatientParticipant has a diagnosis of immunodeficiency or is receiving systemic steroid therapy at a prednisone equivalent dose of >10 mg daily for at least 1 week or other form of immunosuppressive therapy within 7 days prior to Cycle 1 Day 1 (C1D1).
  • EditedPatientParticipant has uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, suspected or active Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2 (COVID-19) infection, disseminated intravascular coagulation, or psychiatric illness/social situations that would limit compliance with study requirements.
  • EditedPatientParticipant has known positive status for human immunodeficiency virus, active or chronic Hepatitis B, or Hepatitis C. Screening is not required.
  • EditedPatientParticipant has any medical condition which, in the opinion of the investigator, places the patientparticipant at an unacceptably high risk for toxicity.
  • EditedAny dysphagia, odynophagia, esophageal dysmotility or stricture, known gastro-intestinal (GI) malabsorption syndrome, or intractable diarrhea that may significantly alter the absorption of orally administered study drug.
  • EditedPatientsParticipants with history of symptomatic orthostatic hypotension within 3 months prior to enrollment. Orthostatic hypotension is defined as a drop in systolic blood pressure (BP) of ≥ 20 mmHg or diastolic BP of ≥ 10 mmHg with assumption of an upright posture.
Nov 10, 2026
Interventions
Changed BXCL701 plus Pembrolizumab→Pembrolizumab. Added Drug: Talabostat; removed Drug: BXCL701 monotherapy. Arm changed Phase 2b monotherapy→Phase 2B (Adenocarcinoma): Talabostat Monotherapy. Arms added: Phase 1B: Talabostat 0.4 mg QD + Pembrolizumab 200 mg·Phase 1B: Talabostat 0.6 mg QD + Pembrolizumab 200 mg·Phase 1B: Talabostat 0.6 mg TDD + Pembrolizumab 200 mg·Phase 2A (SCNC): Talabostat + Pembrolizumab 200 mg·Phase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg·and 1 more
All 6

Phase 1B: Talabostat 0.4 mg QD + Pembrolizumab 200 mg · Phase 1B: Talabostat 0.6 mg QD + Pembrolizumab 200 mg · Phase 1B: Talabostat 0.6 mg TDD + Pembrolizumab 200 mg · Phase 2A (SCNC): Talabostat + Pembrolizumab 200 mg · Phase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg · Phase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg

; arms removed: Phase 1b·Phase 2a·Phase 2b combination
Nov 10, 2026
Primary outcomes
2 added, 2 removed
What changed in the outcomes
  • AddedPhase 2a: Composite Response Rate (CRR)Time frame: Up to approximately 4 years and 4 months
  • AddedPhase 2b: Objective Response Rate (ORR)Time frame: Up to approximately 4 years and 4 months
  • RemovedPhase 2a: Estimate the composite response rate of the combination of BXCL701 + PEMBROTime frame: up to 36 months
  • RemovedPhase 2b: Evaluate response rates in patients treated with the combination of BXCL701 + PEMBRO and with BXCL701 monotherapyTime frame: up to 36 months
Nov 10, 2026
Documents
Secondary outcomes
2 edited, 15 added, 6 removed
What changed in the outcomes
  • EditedPhase 2a: Estimate the median radiographic progressionRadiographic Progression-free survivalSurvival (rPFS) of the combination of BXCL701 and PEMBRO in Cohort A and BTime frame: up to 36 months → Up to approximately 6 years 2 months
  • EditedPhase 2a: Estimate the median durationDuration of responseResponse (DOR) of the combination of BXCL701 and PEMBRO in Cohort A and B.Time frame: up to 36 months → Up to approximately 6 years and 2 months
  • AddedPhase 2a: Prostate Specific Antigen (PSA) Progression-free Survival (PFS)Time frame: Up to approximately 6 years and 2 months
  • AddedPhase 2a: Overall Survival (OS)Time frame: Up to approximately 6 years and 2 months
  • AddedPhase 2a: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From first dose of study drug up to approximately 6 years and 2 months
  • AddedPhase 2a: ≥50% Decline in PSA Value From Baseline (PSA50) Duration of Response (PSA50 DOR)Time frame: Up to approximately 6 years and 2 months
  • AddedPhase 2a: Duration of Stable DiseaseTime frame: Up to approximately 6 years and 2 months
  • AddedPhase 2b: Number of Participants With PSA Decline From Baseline of at Least 50%Time frame: Up to approximately 6 years and 2 months
  • AddedPhase 2b: CRRTime frame: Up to approximately 6 years and 2 months
  • AddedPhase 2b: rPFSTime frame: Up to approximately 6 years and 2 months
  • AddedPhase 2b: PSA PFSTime frame: Up to approximately 6 years and 2 months
  • AddedPhase 2b: OSTime frame: Up to approximately 6 years and 2 months
  • AddedPhase 2b: DORTime frame: Up to approximately 6 years and 2 months
  • AddedPhase 2b: PSA50 DORTime frame: Up to approximately 6 years and 2 months
  • AddedPhase 2b: Duration of Stable DiseaseTime frame: Up to approximately 6 years and 2 months
  • AddedPhase 2a: Plasma Concentration of TalabostatTime frame: Up to approximately 6 years and 2 months
  • AddedPhase 2a: Concentration of Plasma CytokinesTime frame: Up to approximately 6 years and 2 months
  • RemovedPhase 2a: Estimate the median PSA progression-free survival (PSA PFS) of the combination of BXCL701 and PEMBRO in Cohort A and B.Time frame: up to 36 months
  • RemovedPhase 2a: Estimate the median overall survival (OS) of the combination of BXCL701 and PEMBRO in Cohort A and B.Time frame: up to 36 months
  • RemovedPhase 2a: Determine the risk profile of the use of BXCL701 in combination with PEMBRO.Time frame: up to 36 months
  • RemovedPhase 2a: Assess population pK of BXCL701Time frame: Up to 36 months
  • RemovedPhase 2a: Assess pharmacodynamic profile of BXCL701 and PembroTime frame: Up to 36 months
  • RemovedPhase 2b: Estimate the CRR, OS, duration response, rPFS and PSA PFS of the BXCL701+Pembro.Time frame: Up to 36 months
Nov 10, 2026
Title
A Trial of Talabostat (BXCL701) and Pembrolizumab in PatientsParticipants With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Results posted
    Start date Feb 12, 2019→Jun 10, 2019
    Enrollment 98→97
    Eligibility 22 inclusion criteria edited; 15 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedAll patientsparticipants must satisfy the following inclusion and exclusion criteria to be eligible for entry into the trial.
    • EditedPatientParticipant has evidence of progressive, metastatic castration-resistant disease, as defined by Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria.
    • EditedPatientsParticipant with de novo small cell prostate cancer are not required to have received androgen deprivation therapy (ADT).
    • EditedPatientParticipant has histologic evidence of SCNC either with archival tissue or a fresh tumor biopsy obtained during screening. Tumor biopsy tissue must be submitted for a central laboratory pathology review; however, enrollment can proceed if SCNC is determined by a local pathology review.
    • EditedPatientParticipant has previously received at least 1 prior line of cytotoxic chemotherapy. PatientsParticipants who either have refused chemotherapy or are considered unsuitable for chemotherapy may be eligible following discussion with the sponsor.
    • EditedMust be willing to undergo metastatic tumor biopsy during Screening. Requirement may be waived in patientsparticipants without safely accessible lesion or for patientsparticipants with evaluable archival metastatic tumor tissue
    • EditedHas measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) criteria.
    • EditedPatientParticipant has histologically or cytologically confirmed adenocarcinoma of the prostate without small cell neuroendocrine features.
    • EditedPatientsParticipants with soft tissue disease must provide a fresh core or excisional biopsy or archival tissue from a site not previously irradiated for central pathology review; however enrollment may proceed if predominant adenocarcinoma without small cell neuroendocrine features is determined by local pathology review.
    • EditedHas been treated with at least 1 but no more than 2 second generation androgen receptor (AR) pathway target agents (e.g., abiraterone acetate and/or enzalutamide or other next generation agent) and at least 1 regimen/line of taxane containing chemotherapy in the metastatic castration-sensitive prostate cancer (mCSPC) or mCRPC setting. PatientsParticipants with known actionable mutations should have progressed on applicable standard care targeted therapy or have documented intolerance to or be unsuitable for such therapy.
    • EditedPatientParticipant has serum testosterone <50 ng/dL during Screening except for those with de novo small cell prostate cancer.
    • EditedPatientsParticipants with treatment-emergent SCNC without a history of bilateral orchiectomy are required to remain on luteinizing hormone-releasing hormone (LHRH) analog during the course of protocol therapy except for patientsparticipants with de novo small cell prostate cancer.
    • EditedPatientParticipant has Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
    • EditedPatientParticipant is ≥18 years of age.
    • EditedPatientParticipant's acute toxic effects of previous anticancer therapy have resolved to ≤Grade 1 except for Grade 2-3 peripheral neuropathy or any grade of alopecia.
    • EditedPatientParticipant has adequate baseline organ function, as demonstrated by the following:
    • EditedAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × institutional ULN (patientsparticipants with hepatic metastases must have AST/ALT ≤5 × ULN).
    • EditedPatientParticipant has adequate baseline hematologic function, as demonstrated by the following:
    • EditedMale patientsparticipants and their female partners of childbearing potential must agree and commit to use a barrier contraception throughout the duration of the study until at least 6 months following the last dose of study drug, in addition to their female partners using either an intrauterine device or hormonal contraception and continuing until at least 6 months following the last dose of study drug. This criterion may be waived for male patientsparticipants who have had a vasectomy >6 months before signing the informed consent form.
    • EditedException: In the United States, female partners of study participants are not required to use contraception as a condition of their partners' eligibility, but female partners with child bearingchildbearing potential should consider use of effect methods of contraception for the duration of their male partners' study participation and for at least 6 months following the last dose of study medication.
    • EditedPatientParticipant has signed informed consent prior to initiation of any study-specific procedures or treatment.
    • EditedPatientParticipant is able to adhere to the study visit schedule and other protocol requirements, including follow-up for overall survival (OS).
    Exclusion criteria
    • EditedPatientParticipant has received treatment with >2 cytotoxic chemotherapy regimens for castration-resistant prostate cancer (CRPC). Chemotherapy in the hormone-sensitive setting does not count in this assessment provided the last dose was >6 months before study entry. A change in chemotherapy agents due to intolerance after brief exposure may not count in this assessment, pending review with Medical Monitor.
    • EditedPatientParticipant has received external-beam radiation or another systemic anticancer therapy within 14 days or 5 half-lives, whichever is shorter, prior to study treatment.
    • EditedPatientParticipant has received treatment with an investigational systemic anticancer agent within 14 days prior to study drug administration.
    • EditedPatientParticipant has received prior treatment with an anti-PD-1, anti-PD-L1, anti-programmed death ligand 2 (PD-L2) agent or with an agent directed to another co-inhibitory T-cell receptor (e.g., cytotoxic T lymphocyte-associated antigen 4 [CTLA-4], OX-40, CD137) or requires concomitant treatment with DPP4 inhibitors.
    • EditedPatientParticipant has an additional active malignancy that may confound the assessment of the study endpoints. If the patientparticipant has a past cancer history (active malignancy within 2 years prior to study entry) with substantial potential for recurrence, this must be discussed with the sponsor before study entry. PatientsParticipants with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin cancer and carcinomas in situ (including transitional cell carcinoma, anal carcinoma, and melanoma in situ).
    • EditedPatientParticipant has clinically significant cardiovascular disease (e.g., uncontrolled or any New York Heart Association Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial infarction, unstable angina or stroke within 6 months prior to study entry, uncontrolled hypertension or clinically significant arrhythmias not controlled by medication).
    • EditedPatientParticipant has uncontrolled, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease, pulmonary hypertension) that in the opinion of the investigator would put the patientparticipant at significant risk for pulmonary complications during the study.
    • EditedPatientParticipant has brain or leptomeningeal metastases that are symptomatic and progressive on imaging. PatientsParticipants with a history of central nervous system (CNS) metastases must have received appropriate treatment. Central nervous system imaging is not required prior to study entry unless there is a history of CNS involvement or clinical suspicion of CNS involvement. Imaging of patientsparticipants with a prior history of CNS metastases should be compared to prior imaging to discern disease progression.
    • EditedPatientParticipant has an active autoimmune disease or Grade ≥3 non-infectious pneumonitis that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) or treatment with drugs (e.g., neomercazol, carbimazole) that function to decrease the generation of thyroid hormone by a hyperfunctioning thyroid gland (e.g., in Graves' disease) is not considered a form of systemic treatment of an autoimmune disease.
    • EditedPatientParticipant has a diagnosis of immunodeficiency or is receiving systemic steroid therapy at a prednisone equivalent dose of >10 mg daily for at least 1 week or other form of immunosuppressive therapy within 7 days prior to Cycle 1 Day 1 (C1D1).
    • EditedPatientParticipant has uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, suspected or active Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2 (COVID-19) infection, disseminated intravascular coagulation, or psychiatric illness/social situations that would limit compliance with study requirements.
    • EditedPatientParticipant has known positive status for human immunodeficiency virus, active or chronic Hepatitis B, or Hepatitis C. Screening is not required.
    • EditedPatientParticipant has any medical condition which, in the opinion of the investigator, places the patientparticipant at an unacceptably high risk for toxicity.
    • EditedAny dysphagia, odynophagia, esophageal dysmotility or stricture, known gastro-intestinal (GI) malabsorption syndrome, or intractable diarrhea that may significantly alter the absorption of orally administered study drug.
    • EditedPatientsParticipants with history of symptomatic orthostatic hypotension within 3 months prior to enrollment. Orthostatic hypotension is defined as a drop in systolic blood pressure (BP) of ≥ 20 mmHg or diastolic BP of ≥ 10 mmHg with assumption of an upright posture.
    Primary outcomes 2 added, 2 removed
    What changed in the outcomes
    • AddedPhase 2a: Composite Response Rate (CRR)Time frame: Up to approximately 4 years and 4 months
    • AddedPhase 2b: Objective Response Rate (ORR)Time frame: Up to approximately 4 years and 4 months
    • RemovedPhase 2a: Estimate the composite response rate of the combination of BXCL701 + PEMBROTime frame: up to 36 months
    • RemovedPhase 2b: Evaluate response rates in patients treated with the combination of BXCL701 + PEMBRO and with BXCL701 monotherapyTime frame: up to 36 months
    Secondary outcomes 2 edited, 15 added, 6 removed
    What changed in the outcomes
    • EditedPhase 2a: Estimate the median radiographic progressionRadiographic Progression-free survivalSurvival (rPFS) of the combination of BXCL701 and PEMBRO in Cohort A and BTime frame: up to 36 months → Up to approximately 6 years 2 months
    • EditedPhase 2a: Estimate the median durationDuration of responseResponse (DOR) of the combination of BXCL701 and PEMBRO in Cohort A and B.Time frame: up to 36 months → Up to approximately 6 years and 2 months
    • AddedPhase 2a: Prostate Specific Antigen (PSA) Progression-free Survival (PFS)Time frame: Up to approximately 6 years and 2 months
    • AddedPhase 2a: Overall Survival (OS)Time frame: Up to approximately 6 years and 2 months
    • AddedPhase 2a: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From first dose of study drug up to approximately 6 years and 2 months
    • AddedPhase 2a: ≥50% Decline in PSA Value From Baseline (PSA50) Duration of Response (PSA50 DOR)Time frame: Up to approximately 6 years and 2 months
    • AddedPhase 2a: Duration of Stable DiseaseTime frame: Up to approximately 6 years and 2 months
    • AddedPhase 2b: Number of Participants With PSA Decline From Baseline of at Least 50%Time frame: Up to approximately 6 years and 2 months
    • AddedPhase 2b: CRRTime frame: Up to approximately 6 years and 2 months
    • AddedPhase 2b: rPFSTime frame: Up to approximately 6 years and 2 months
    • AddedPhase 2b: PSA PFSTime frame: Up to approximately 6 years and 2 months
    • AddedPhase 2b: OSTime frame: Up to approximately 6 years and 2 months
    • AddedPhase 2b: DORTime frame: Up to approximately 6 years and 2 months
    • AddedPhase 2b: PSA50 DORTime frame: Up to approximately 6 years and 2 months
    • AddedPhase 2b: Duration of Stable DiseaseTime frame: Up to approximately 6 years and 2 months
    • AddedPhase 2a: Plasma Concentration of TalabostatTime frame: Up to approximately 6 years and 2 months
    • AddedPhase 2a: Concentration of Plasma CytokinesTime frame: Up to approximately 6 years and 2 months
    • RemovedPhase 2a: Estimate the median PSA progression-free survival (PSA PFS) of the combination of BXCL701 and PEMBRO in Cohort A and B.Time frame: up to 36 months
    • RemovedPhase 2a: Estimate the median overall survival (OS) of the combination of BXCL701 and PEMBRO in Cohort A and B.Time frame: up to 36 months
    • RemovedPhase 2a: Determine the risk profile of the use of BXCL701 in combination with PEMBRO.Time frame: up to 36 months
    • RemovedPhase 2a: Assess population pK of BXCL701Time frame: Up to 36 months
    • RemovedPhase 2a: Assess pharmacodynamic profile of BXCL701 and PembroTime frame: Up to 36 months
    • RemovedPhase 2b: Estimate the CRR, OS, duration response, rPFS and PSA PFS of the BXCL701+Pembro.Time frame: Up to 36 months
    Interventions Changed BXCL701 plus Pembrolizumab→Pembrolizumab. Added Drug: Talabostat; removed Drug: BXCL701 monotherapy. Arm changed Phase 2b monotherapy→Phase 2B (Adenocarcinoma): Talabostat Monotherapy. Arms added: Phase 1B: Talabostat 0.4 mg QD + Pembrolizumab 200 mg·Phase 1B: Talabostat 0.6 mg QD + Pembrolizumab 200 mg·Phase 1B: Talabostat 0.6 mg TDD + Pembrolizumab 200 mg·Phase 2A (SCNC): Talabostat + Pembrolizumab 200 mg·Phase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg·and 1 more
    All 6

    Phase 1B: Talabostat 0.4 mg QD + Pembrolizumab 200 mg · Phase 1B: Talabostat 0.6 mg QD + Pembrolizumab 200 mg · Phase 1B: Talabostat 0.6 mg TDD + Pembrolizumab 200 mg · Phase 2A (SCNC): Talabostat + Pembrolizumab 200 mg · Phase 2A (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg · Phase 2B (Adenocarcinoma): Talabostat + Pembrolizumab 200 mg

    ; arms removed: Phase 1b·Phase 2a·Phase 2b combination
    Title A Trial of Talabostat (BXCL701) and Pembrolizumab in PatientsParticipants With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
    + 4 other changes: verification date, description, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03910660
Lead sponsor
BioXcel Therapeutics Inc
Responsible party
Sponsor
First posted
Apr 10, 2019
Start date
Jun 10, 2019
Primary completion
Oct 31, 2023
Completion
Aug 31, 2025
Results posted
Nov 10, 2026
Last update
Nov 10, 2026

Study contacts

BioXcel Therapeutics Medical Monitor
study director · BioXcel Therapeutics
BioXcel Therapeutics Medical Monitor
study chair · BioXcel Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Talabostat

Start the discussion